Lixte Biotechnology, Inc. - חוב לטווח קצר של החברה LIXT
The lack of stable cash flow due to the clinical status of its developments makes Lixte Biotechnology (LIXT) dependent on external funding. Current short-term liabilities displayed on the GURU.Markets platform confirm this hypothesis, with the latest value recorded as 0.00. The business relies on licensing inhibitor formulas to third-party behemoths, while scalability is driven by global sales of patented drugs with minimal production costs.
%3A%20%D7%94%D7%9C%D7%95%D7%95%D7%90%D7%95%D7%AA%20%D7%95%D7%90%D7%A9%D7%A8%D7%90%D7%99%20%D7%9C%D7%98%D7%95%D7%95%D7%97%20%D7%A7%D7%A6%D7%A8%20%D7%A9%D7%9C%20%D7%94%D7%97%D7%91%D7%A8%D7%94&width=1200&height=400&colorIndex=0&v=mvrk6wqv.ssk-7as46ww&start=20220704&end=20261028&filename=GURU_Markets_-_LIXT_-_Lixte-Biotechnology_-_Company-Short-Term-Loans-and-Borrowings "LIXT Lixte Biotechnology: חובות לטווח קצר של החברה בטווח 04.07.2022 - 06.07.2026 | 👁️GURU.Markets👁️")
Lixte Biotechnology, Inc. - פילוחים אנליטיים ומדדי מפתח (LIXT)
Geopolitical tensions and sanctions are complicating the logistics of reagents for Lixte Biotechnology (LIXT) oncology research, directly impacting operating expenses. The short-term debt time series captures obligations of up to one year; a decrease in this metric could signal either a post-crisis balance sheet recovery or a loss of access to credit, which is critical if drug development timelines are extended.